Commentary
Video
April 3, 2025
Author(s):
Conference|EBMT Meeting
Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.
Kiavasch Mohammad Nejad Farid, MD, Heidelberg University Hospital, discusses the efficacy findings from a study of the novel second-generation BCMA-directed CAR T-cell construct MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Related Videos
Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCLDr Mateos on Long-Term OS Data From the Phase 3 CARTITUDE-4 Study of Cilta-Cel in Lenalidomide-Refractory Multiple MyelomaDr Politikos on the Immune Reconstitution Profiles of Orca-T and CD34 Allograft Recipients in Hematologic MalignanciesDr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in MyelofibrosisDr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AMLDr Paredes on the Association Between Fiber Intake and Improved Survival With Reduced GI aGVHD After Allo-HCTDr Wang on the Role of Menin Inhibitors in Genetically Defined AML SubtypesDr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCLDr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer
Related Content
View More
ConferencePrecision Medicine in Oncology®
April 3rd 2025
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies
March 26th 2025
Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc
April 2nd 2025
Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease
November 28th 2024
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
April 2nd 2025
Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD
April 2nd 2025
ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL
Latest Conference Coverage
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell MalignanciesUpdated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative DiseasePacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host DiseaseAxi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL
View More Latest Conference Coverage
Recent Content
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell MalignanciesNewly Approved ADCs Expand Options in HR+ Metastatic Breast CancerKidney Cancer Awareness Month Spotlights Early Symptom Recognition, Current Challenges, and Key Treatment Advancements